Each month our editorial team sifts through hundreds of papers and curates notable findings—for practitioners and informed readers who want to stay current with the evidence. Subscribe to the monthly Research Digest for expert analysis and concise summaries of key papers.
1 paper
Researchers are again studying classic psychedelics, including LSD, as possible tools to help people with addiction. Early work and a few small studies suggest some psychedelics can change the brain, change people’s outlook, and sometimes reduce harmful use. But the evidence is still limited, and most strong claims come from other psychedelics (like psilocybin or ibogaine) or from general studies of how these drugs work in the brain. In short: there are promising signs, some real risks, and a lot we do not yet know. Scientists say we need larger, careful trials, clear safety rules, and better ways to tell how much benefit comes from the drug itself versus the therapy and setting around it.
Researchers around the world have started clinical studies again to see if psychedelic drugs can help treat serious mental health problems. This work picks up after research that stopped around the 1950s. Scientists are running controlled studies to test whether these substances can safely reduce problems like depression, anxiety, addiction…
